{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,2]],"date-time":"2026-10-02T10:45:13Z","timestamp":1790937913113,"version":"4.1.0"},"reference-count":138,"publisher":"MDPI AG","issue":"15","license":[{"start":{"date-parts":[[2022,7,27]],"date-time":"2022-07-27T00:00:00Z","timestamp":1658880000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Cells"],"abstract":"<jats:p>Multiple Myeloma (MM) is a hematologic malignancy characterized by the proliferation of monoclonal plasma cells localized within the bone marrow. Bone disease with associated osteolytic lesions is a hallmark of MM and develops in the majority of MM patients. Approximately half of patients with bone disease will experience skeletal-related events (SREs), such as spinal cord compression and pathologic fractures, which increase the risk of mortality by 20\u201340%. At the cellular level, bone disease results from a tumor-cell-driven imbalance between osteoclast bone resorption and osteoblast bone formation, thereby creating a favorable cellular environment for bone resorption. The use of osteoclast inhibitory therapies with bisphosphonates, such as zoledronic acid and the RANKL inhibitor denosumab, have been shown to delay and lower the risk of SREs, as well as the need for surgery or radiation therapy to treat severe bone complications. This review outlines our current understanding of the molecular underpinnings of bone disease, available therapeutic options, and highlights recent advances in the management of MM-related bone disease.<\/jats:p>","DOI":"10.3390\/cells11152308","type":"journal-article","created":{"date-parts":[[2022,7,27]],"date-time":"2022-07-27T21:11:05Z","timestamp":1658956265000},"page":"2308","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":68,"title":["Bone Disease in Multiple Myeloma: Biologic and Clinical Implications"],"prefix":"10.3390","volume":"11","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-2269-8695","authenticated-orcid":false,"given":"Zachary S.","family":"Bernstein","sequence":"first","affiliation":[{"name":"Center for Multiple Myeloma, Massachusetts General Hospital Cancer Center, Boston, MA 02114, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"E. Bridget","family":"Kim","sequence":"additional","affiliation":[{"name":"Department of Pharmacy, Massachusetts General Hospital, Boston, MA 02114, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Noopur","family":"Raje","sequence":"additional","affiliation":[{"name":"Center for Multiple Myeloma, Massachusetts General Hospital Cancer Center, Boston, MA 02114, USA"},{"name":"Harvard Medical School, Boston, MA 02115, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2022,7,27]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"e352","DOI":"10.1016\/j.clml.2020.01.017","article-title":"Consensus guidelines on the diagnosis of multiple myeloma and related disorders: Recommendations of the myeloma canada research network consensus guideline consortium","volume":"20","author":"Bergstrom","year":"2020","journal-title":"Clin. Lymphoma Myeloma Leuk."},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1158\/1078-0432.CCR-18-1537","article-title":"Role of the RANK\/RANKL pathway in multiple myeloma","volume":"25","author":"Raje","year":"2019","journal-title":"Clin. Cancer Res."},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1016\/j.mayocp.2015.11.007","article-title":"Multiple Myeloma: Diagnosis and Treatment","volume":"91","author":"Rajkumar","year":"2016","journal-title":"Mayo Clin. Proc."},{"key":"ref_4","doi-asserted-by":"crossref","unstructured":"The International Myeloma Working Group (2003). Criteria for the classification of monoclonal gammopathies, multiple myeloma and related disorders: A report of the International Myeloma Working Group. Br. J. Haematol., 121, 749\u2013757.","DOI":"10.1046\/j.1365-2141.2003.04355.x"},{"key":"ref_5","unstructured":"Global Burden of Disease Cancer Collaboration, Fitzmaurice, C., Abate, D., Abbasi, N., Abbastabar, H., Abd-Allah, F., Abdel-Rahman, O., Abdelalim, A., Abdoli, A., and Abdollahpour, I. (2019). Global, regional, and national cancer incidence, mortality, years of life lost, years lived with disability, and disability-adjusted life-years for 29 cancer groups, 1990 to 2017: A systematic analysis for the global burden of disease study. JAMA Oncol., 5, 1749\u20131768."},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"3111","DOI":"10.1038\/s41375-020-01051-x","article-title":"Changing paradigms in diagnosis and treatment of monoclonal gammopathy of undetermined significance (MGUS) and smoldering multiple myeloma (SMM)","volume":"34","author":"Ho","year":"2020","journal-title":"Leukemia"},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"90501","DOI":"10.18632\/oncotarget.18765","article-title":"The therapeutic potential of cell cycle targeting in multiple myeloma","volume":"8","author":"Maes","year":"2017","journal-title":"Oncotarget"},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"1121","DOI":"10.1038\/leu.2010.60","article-title":"Monoclonal gammopathy of undetermined significance (MGUS) and smoldering (asymptomatic) multiple myeloma: IMWG consensus perspectives risk factors for progression and guidelines for monitoring and management","volume":"24","author":"Kyle","year":"2010","journal-title":"Leukemia"},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"100215","DOI":"10.1016\/j.jbo.2018.100215","article-title":"Incidence of skeletal-related events among multiple myeloma patients in the United States at oncology clinics: Observations from real-world data","volume":"14","author":"Kim","year":"2018","journal-title":"J. Bone Oncol."},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"282","DOI":"10.1182\/bloodadvances.2016002493","article-title":"Recent trends in multiple myeloma incidence and survival by age, race, and ethnicity in the United States","volume":"1","author":"Costa","year":"2017","journal-title":"Blood Adv."},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"5412","DOI":"10.1182\/blood-2008-12-194241","article-title":"Monoclonal gammopathy of undetermined significance (MGUS) consistently precedes multiple myeloma: A prospective study","volume":"113","author":"Landgren","year":"2009","journal-title":"Blood"},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"1228","DOI":"10.1200\/JCO.18.02096","article-title":"Treatment of multiple myeloma: ASCO and CCO joint clinical practice guideline","volume":"37","author":"Mikhael","year":"2019","journal-title":"J. Clin. Oncol."},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1200\/JOP.19.00244","article-title":"Current treatment strategies for multiple myeloma","volume":"16","author":"Branagan","year":"2020","journal-title":"JCO Oncol. Pract."},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"1122","DOI":"10.1038\/leu.2013.313","article-title":"Continued improvement in survival in multiple myeloma: Changes in early mortality and outcomes in older patients","volume":"28","author":"Kumar","year":"2014","journal-title":"Leukemia"},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"2516","DOI":"10.1182\/blood-2007-10-116129","article-title":"Improved survival in multiple myeloma and the impact of novel therapies","volume":"111","author":"Kumar","year":"2008","journal-title":"Blood"},{"key":"ref_16","first-page":"1178224219868235","article-title":"Multiple myeloma: An overview of management","volume":"13","author":"Bird","year":"2019","journal-title":"Palliat. Care Soc. Pract."},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"135","DOI":"10.1016\/j.bone.2010.06.016","article-title":"Osteoblast function in myeloma","volume":"48","author":"Roodman","year":"2011","journal-title":"Bone"},{"key":"ref_18","doi-asserted-by":"crossref","unstructured":"Ban, J., Fock, V., Aryee, D.N.T., and Kovar, H. (2021). Mechanisms, diagnosis and treatment of bone metastases. Cells, 10.","DOI":"10.3390\/cells10112944"},{"key":"ref_19","doi-asserted-by":"crossref","unstructured":"Padala, S.A., Barsouk, A., Barsouk, A., Rawla, P., Vakiti, A., Kolhe, R., Kota, V., and Ajebo, G.H. (2021). Epidemiology, staging, and management of multiple myeloma. Med. Sci., 9.","DOI":"10.3390\/medsci9010003"},{"key":"ref_20","doi-asserted-by":"crossref","unstructured":"Coluzzi, F., Rolke, R., and Mercadante, S. (2019). Pain management in patients with multiple myeloma: An update. Cancers, 11.","DOI":"10.3390\/cancers11122037"},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"195","DOI":"10.2217\/fon-2017-0403","article-title":"Denosumab for the treatment of bone disease in solid tumors and multiple myeloma","volume":"14","author":"Yee","year":"2018","journal-title":"Future Oncol."},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"2911","DOI":"10.1200\/JCO.2017.72.2975","article-title":"Prospective evaluation of magnetic resonance imaging and [(18)F]fluorodeoxyglucose positron emission tomography-computed tomography at diagnosis and before maintenance therapy in symptomatic patients with multiple myeloma included in the IFM\/DFCI 2009 trial: Results of the IMAJEM study","volume":"35","author":"Moreau","year":"2017","journal-title":"J. Clin. Oncol."},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"e599","DOI":"10.1038\/bcj.2017.78","article-title":"Whole-body computed tomography versus conventional skeletal survey in patients with multiple myeloma: A study of the International Myeloma Working Group","volume":"7","author":"Hillengass","year":"2017","journal-title":"Blood Cancer J."},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"158","DOI":"10.1016\/S0009-9260(67)80010-2","article-title":"The radiological demonstration of osseous metastases. Experimental observations","volume":"18","author":"Edelstyn","year":"1967","journal-title":"Clin. Radiol."},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"773","DOI":"10.1007\/s00256-018-3066-6","article-title":"Value of low-dose whole-body CT in the management of patients with multiple myeloma and precursor states","volume":"48","author":"Simeone","year":"2019","journal-title":"Skeletal. Radiol."},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"1539","DOI":"10.1016\/j.ejca.2005.11.037","article-title":"The role of anatomic and functional staging in myeloma: Description of Durie\/Salmon plus staging system","volume":"42","author":"Durie","year":"2006","journal-title":"Eur. J. Cancer"},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"206","DOI":"10.3109\/07357907.2013.764565","article-title":"Multiple myeloma lesion detection with whole body CT versus radiographic skeletal survey","volume":"31","author":"Princewill","year":"2013","journal-title":"Cancer Investig."},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"e415","DOI":"10.3324\/haematol.2016.146092","article-title":"Baseline bone involvement in multiple myeloma\u2014A prospective comparison of conventional X-ray, low-dose computed tomography, and 18flourodeoxyglucose positron emission tomography in previously untreated patients","volume":"101","author":"Hinge","year":"2016","journal-title":"Haematologica"},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"1429","DOI":"10.2214\/ajr.178.6.1781429","article-title":"Multidetector CT of the spine in multiple myeloma: Comparison with MR imaging and radiography","volume":"178","author":"Mahnken","year":"2002","journal-title":"AJR Am. J. Roentgenol."},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"483","DOI":"10.1148\/radiology.154.2.3966137","article-title":"Multiple myeloma: Evaluation by CT","volume":"154","author":"Schreiman","year":"1985","journal-title":"Radiology"},{"key":"ref_31","doi-asserted-by":"crossref","unstructured":"Du, J.-S., Yen, C.-H., Hsu, C.-M., and Hsiao, H.-H. (2021). Management of myeloma bone lesions. Int. J. Mol. Sci., 22.","DOI":"10.3390\/ijms22073389"},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"1860","DOI":"10.1002\/cncr.22991","article-title":"Pathologic fractures correlate with reduced survival in patients with malignant bone disease","volume":"110","author":"Saad","year":"2007","journal-title":"Cancer"},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"1253","DOI":"10.2165\/00003495-200161090-00003","article-title":"The clinical and cost considerations of bisphosphonates in preventing bone complications in patients with metastatic breast cancer or multiple myeloma","volume":"61","author":"McCloskey","year":"2001","journal-title":"Drugs"},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"797","DOI":"10.1152\/physrev.00012.2019","article-title":"Bone metastasis: Mechanisms, therapies, and biomarkers","volume":"101","author":"Coleman","year":"2021","journal-title":"Physiol. Rev."},{"key":"ref_35","first-page":"4","article-title":"An overview of bone cells and their regulating factors of differentiation","volume":"15","author":"Mohamed","year":"2008","journal-title":"Malays. J. Med. Sci."},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"211","DOI":"10.1016\/0012-1606(73)90351-5","article-title":"Pyrophosphate stimulation of calcium uptake into cultured embryonic bones. Fine structure of matrix vesicles and their role in calcification","volume":"34","author":"Anderson","year":"1973","journal-title":"Dev. Biol."},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"3992","DOI":"10.1182\/blood-2006-05-026112","article-title":"Multiple myeloma bone disease: Pathophysiology of osteoblast inhibition","volume":"108","author":"Giuliani","year":"2006","journal-title":"Blood"},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"104","DOI":"10.1111\/j.1600-0609.1997.tb00932.x","article-title":"Abnormal bone turnover in monoclonal gammopathy of undetermined significance: Analyses of type I collagen telopeptide, osteocalcin, bone-specific alkaline phosphatase and propeptides of type I and type III procollagens","volume":"58","author":"Vejlgaard","year":"1997","journal-title":"Eur. J. Haematol."},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"755","DOI":"10.1016\/S0092-8674(00)80258-5","article-title":"Targeted disruption of Cbfa1 results in a complete lack of bone formation owing to maturational arrest of osteoblasts","volume":"89","author":"Komori","year":"1997","journal-title":"Cell"},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"6222","DOI":"10.1128\/MCB.22.17.6222-6233.2002","article-title":"High bone resorption in adult aging transgenic mice overexpressing Cbfa1\/Runx2 in cells of the osteoblastic lineage","volume":"22","author":"Geoffroy","year":"2002","journal-title":"Mol. Cell. Biol."},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"345","DOI":"10.1016\/j.bbrc.2006.02.147","article-title":"Osteoclast and its roles in calcium metabolism and bone development and remodeling","volume":"343","author":"Li","year":"2006","journal-title":"Biochem. Biophys. Res. Commun."},{"key":"ref_42","doi-asserted-by":"crossref","first-page":"651161","DOI":"10.3389\/fcell.2021.651161","article-title":"Regulation of osteoclastogenesis and bone resorption by miRNAs","volume":"9","author":"Inoue","year":"2021","journal-title":"Front. Cell Dev. Biol."},{"key":"ref_43","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1016\/j.jbo.2013.04.001","article-title":"Myeloma bone disease: Pathophysiology and management","volume":"2","author":"Silbermann","year":"2013","journal-title":"J. Bone Oncol."},{"key":"ref_44","doi-asserted-by":"crossref","first-page":"3235","DOI":"10.1210\/en.2004-1583","article-title":"The inhibition of RANKL causes greater suppression of bone resorption and hypercalcemia compared with bisphosphonates in two models of humoral hypercalcemia of malignancy","volume":"146","author":"Morony","year":"2005","journal-title":"Endocrinology"},{"key":"ref_45","doi-asserted-by":"crossref","first-page":"315","DOI":"10.1038\/16852","article-title":"OPGL is a key regulator of osteoclastogenesis, lymphocyte development and lymph-node organogenesis","volume":"397","author":"Kong","year":"1999","journal-title":"Nature"},{"key":"ref_46","doi-asserted-by":"crossref","first-page":"1260","DOI":"10.1101\/gad.12.9.1260","article-title":"osteoprotegerin-deficient mice develop early onset osteoporosis and arterial calcification","volume":"12","author":"Bucay","year":"1998","journal-title":"Genes Dev."},{"key":"ref_47","doi-asserted-by":"crossref","first-page":"3597","DOI":"10.1073\/pnas.95.7.3597","article-title":"Osteoclast differentiation factor is a ligand for osteoprotegerin\/osteoclastogenesis-inhibitory factor and is identical to TRANCE\/RANKL","volume":"95","author":"Yasuda","year":"1998","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"ref_48","doi-asserted-by":"crossref","first-page":"165","DOI":"10.1016\/S0092-8674(00)81569-X","article-title":"Osteoprotegerin ligand is a cytokine that regulates osteoclast differentiation and activation","volume":"93","author":"Lacey","year":"1998","journal-title":"Cell"},{"key":"ref_49","doi-asserted-by":"crossref","first-page":"33","DOI":"10.4137\/CGM.S16817","article-title":"Bone disease in multiple myeloma: Pathophysiology and management","volume":"7","author":"Hameed","year":"2014","journal-title":"Cancer Growth Metastasis"},{"key":"ref_50","doi-asserted-by":"crossref","first-page":"1278","DOI":"10.1158\/1078-0432.CCR-10-1804","article-title":"Advances in the biology and treatment of bone disease in multiple myeloma","volume":"17","author":"Raje","year":"2011","journal-title":"Clin. Cancer Res."},{"key":"ref_51","doi-asserted-by":"crossref","first-page":"6289","DOI":"10.1158\/1078-0432.CCR-08-0666","article-title":"Zoledronic acid markedly improves bone mineral density for patients with monoclonal gammopathy of undetermined significance and bone loss","volume":"14","author":"Berenson","year":"2008","journal-title":"Clin. Cancer Res."},{"key":"ref_52","doi-asserted-by":"crossref","first-page":"2529","DOI":"10.1002\/jbmr.2387","article-title":"Unveiling skeletal fragility in patients diagnosed with MGUS: No longer a condition of undetermined significance?","volume":"29","author":"Drake","year":"2014","journal-title":"J. Bone Miner. Res."},{"key":"ref_53","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1159\/000162282","article-title":"Prevalence of monoclonal gammopathy of undetermined significance\/myeloma in patients with acute osteoporotic vertebral fractures","volume":"120","author":"Golombick","year":"2008","journal-title":"Acta Haematol."},{"key":"ref_54","doi-asserted-by":"crossref","first-page":"818","DOI":"10.1136\/bmj.38376.401701.8F","article-title":"Utility of testing for monoclonal bands in serum of patients with suspected osteoporosis: Retrospective, cross sectional study","volume":"330","author":"Abrahamsen","year":"2005","journal-title":"BMJ"},{"key":"ref_55","doi-asserted-by":"crossref","first-page":"8467","DOI":"10.2147\/OTT.S192490","article-title":"Prevention of skeletal related events in multiple myeloma: Focus on the RANK-L pathway in the treatment of multiple myeloma","volume":"12","author":"Parrondo","year":"2019","journal-title":"OncoTargets Ther."},{"key":"ref_56","doi-asserted-by":"crossref","first-page":"290","DOI":"10.1016\/j.bcmd.2004.01.001","article-title":"Pathogenesis of myeloma bone disease","volume":"32","author":"Roodman","year":"2004","journal-title":"Blood Cells Mol. Dis."},{"key":"ref_57","doi-asserted-by":"crossref","first-page":"2472","DOI":"10.1182\/blood-2004-12-4986","article-title":"Myeloma cells block RUNX2\/CBFA1 activity in human bone marrow osteoblast progenitors and inhibit osteoblast formation and differentiation","volume":"106","author":"Giuliani","year":"2005","journal-title":"Blood"},{"key":"ref_58","first-page":"73","article-title":"Dkk-1 and IL-7 in plasma of patients with multiple myeloma prevent differentiation of mesenchymal stem cells into osteoblasts","volume":"4","author":"Nierste","year":"2014","journal-title":"Am. J. Blood Res."},{"key":"ref_59","doi-asserted-by":"crossref","first-page":"1643","DOI":"10.1172\/JCI0215687","article-title":"Increased production of IL-7 uncouples bone formation from bone resorption during estrogen deficiency","volume":"110","author":"Weitzmann","year":"2002","journal-title":"J. Clin. Investig."},{"key":"ref_60","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1007\/BF00163574","article-title":"Myeloma affects both the growth and function of human osteoblast-like cells","volume":"10","author":"Evans","year":"1992","journal-title":"Clin. Exp. Metastasis"},{"key":"ref_61","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1046\/j.1365-2141.2003.04374.x","article-title":"Upregulation of osteoblast apoptosis by malignant plasma cells: A role in myeloma bone disease","volume":"122","author":"Silvestris","year":"2003","journal-title":"Br. J. Haematol."},{"key":"ref_62","doi-asserted-by":"crossref","first-page":"1860","DOI":"10.1056\/NEJMra041875","article-title":"Multiple Myeloma","volume":"351","author":"Kyle","year":"2004","journal-title":"N. Engl. J. Med."},{"key":"ref_63","doi-asserted-by":"crossref","first-page":"1104","DOI":"10.1182\/blood.V87.3.1104.bloodjournal8731104","article-title":"Multiple myeloma cell adhesion-induced interleukin-6 expression in bone marrow stromal cells involves activation of NF-kappa B","volume":"87","author":"Chauhan","year":"1996","journal-title":"Blood"},{"key":"ref_64","doi-asserted-by":"crossref","first-page":"1655","DOI":"10.1056\/NEJMra030831","article-title":"Mechanisms of bone metastasis","volume":"350","author":"Roodman","year":"2004","journal-title":"N. Engl. J. Med."},{"key":"ref_65","doi-asserted-by":"crossref","first-page":"1495","DOI":"10.1182\/blood-2006-06-029298","article-title":"Receptor activator of nuclear factor (NF)\u2013\u03baB ligand (RANKL) increases vascular permeability: Impaired permeability and angiogenesis in eNOS-deficient mice","volume":"109","author":"Min","year":"2006","journal-title":"Blood"},{"key":"ref_66","doi-asserted-by":"crossref","first-page":"1639","DOI":"10.1007\/s00520-016-3543-1","article-title":"Hypercalcaemia and hypocalcaemia: Finding the balance","volume":"25","author":"Body","year":"2017","journal-title":"Support Care Cancer"},{"key":"ref_67","doi-asserted-by":"crossref","first-page":"426","DOI":"10.1200\/JOP.2016.011155","article-title":"Cancer-related hypercalcemia","volume":"12","author":"Goldner","year":"2016","journal-title":"J. Oncol. Pract."},{"key":"ref_68","doi-asserted-by":"crossref","first-page":"3527","DOI":"10.1182\/blood.V98.13.3527","article-title":"Myeloma cells induce imbalance in the osteoprotegerin\/osteoprotegerin ligand system in the human bone marrow environment","volume":"98","author":"Giuliani","year":"2001","journal-title":"Blood"},{"key":"ref_69","doi-asserted-by":"crossref","first-page":"2269","DOI":"10.1182\/blood.V98.7.2269","article-title":"Serum osteoprotegerin levels are reduced in patients with multiple myeloma with lytic bone disease","volume":"98","author":"Seidel","year":"2001","journal-title":"Blood"},{"key":"ref_70","doi-asserted-by":"crossref","first-page":"1064","DOI":"10.1182\/blood-2003-02-0380","article-title":"Soluble receptor activator of nuclear factor \u03baB ligand\u2013osteoprotegerin ratio predicts survival in multiple myeloma: Proposal for a novel prognostic index","volume":"102","author":"Terpos","year":"2003","journal-title":"Blood"},{"key":"ref_71","doi-asserted-by":"crossref","first-page":"334","DOI":"10.1182\/blood-2006-11-059188","article-title":"The proteasome inhibitor bortezomib affects osteoblast differentiation in vitro and in vivo in multiple myeloma patients","volume":"110","author":"Giuliani","year":"2007","journal-title":"Blood"},{"key":"ref_72","doi-asserted-by":"crossref","first-page":"1102","DOI":"10.1038\/sj.leu.2403758","article-title":"High serum bone-specific alkaline phosphatase level after bortezomib-combined therapy in refractory multiple myeloma: Possible role of bortezomib on osteoblast differentiation","volume":"19","author":"Shimazaki","year":"2005","journal-title":"Leukemia"},{"key":"ref_73","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1111\/j.1365-2141.2005.05733.x","article-title":"Response to bortezomib is associated to osteoblastic activation in patients with multiple myeloma","volume":"131","author":"Zangari","year":"2005","journal-title":"Br. J. Haematol."},{"key":"ref_74","doi-asserted-by":"crossref","first-page":"109","DOI":"10.3816\/CLM.2006.n.047","article-title":"Response to bortezomib and activation of osteoblasts in multiple myeloma","volume":"7","author":"Zangari","year":"2006","journal-title":"Clin. Lymphoma Myeloma"},{"key":"ref_75","doi-asserted-by":"crossref","first-page":"325","DOI":"10.1080\/17474086.2018.1447921","article-title":"Possible targets to treat myeloma-related osteoclastogenesis","volume":"11","author":"Bolzoni","year":"2018","journal-title":"Expert Rev. Hematol."},{"key":"ref_76","doi-asserted-by":"crossref","first-page":"200","DOI":"10.1016\/j.bbrc.2005.05.098","article-title":"Proteasome inhibitors abrogate osteoclast differentiation and osteoclast function","volume":"333","author":"Zavrski","year":"2005","journal-title":"Biochem. Biophys. Res. Commun."},{"key":"ref_77","doi-asserted-by":"crossref","first-page":"387.e381","DOI":"10.1016\/j.exphem.2012.11.005","article-title":"Immunomodulatory drugs lenalidomide and pomalidomide inhibit multiple myeloma-induced osteoclast formation and the RANKL\/OPG ratio in the myeloma microenvironment targeting the expression of adhesion molecules","volume":"41","author":"Bolzoni","year":"2013","journal-title":"Exp. Hematol."},{"key":"ref_78","doi-asserted-by":"crossref","first-page":"S4","DOI":"10.1186\/ar2168","article-title":"Multiple myeloma\/hypercalcemia","volume":"9","author":"Oyajobi","year":"2007","journal-title":"Arthritis Res. Ther."},{"key":"ref_79","doi-asserted-by":"crossref","first-page":"409","DOI":"10.1111\/ejh.12923","article-title":"Hypercalcemia remains an adverse prognostic factor for newly diagnosed multiple myeloma patients in the era of novel antimyeloma therapies","volume":"99","author":"Zagouri","year":"2017","journal-title":"Eur. J. Haematol."},{"key":"ref_80","doi-asserted-by":"crossref","first-page":"483","DOI":"10.1007\/s11914-017-0397-5","article-title":"Myeloma and bone disease","volume":"15","author":"Panaroni","year":"2017","journal-title":"Curr. Osteoporos. Rep."},{"key":"ref_81","doi-asserted-by":"crossref","first-page":"899","DOI":"10.1016\/S0140-6736(70)92070-2","article-title":"Inorganic pyrophosphate in plasma, urine, and synovial fluid of patients with pyrophosphate arthropathy (chondrocalcinosis or pseudogout)","volume":"296","author":"Russell","year":"1970","journal-title":"Lancet"},{"key":"ref_82","doi-asserted-by":"crossref","first-page":"617","DOI":"10.1016\/j.bone.2005.05.003","article-title":"Novel insights into actions of bisphosphonates on bone: Differences in interactions with hydroxyapatite","volume":"38","author":"Nancollas","year":"2006","journal-title":"Bone"},{"key":"ref_83","doi-asserted-by":"crossref","first-page":"450","DOI":"10.2174\/1871530318666180423122409","article-title":"Identifying potential therapeutics for osteoporosis by exploiting the relationship between mevalonate pathway and bone metabolism","volume":"18","author":"Hasan","year":"2018","journal-title":"Endocr. Metab. Immune Disord. Drug Targets"},{"key":"ref_84","doi-asserted-by":"crossref","first-page":"2387","DOI":"10.1158\/1078-0432.CCR-07-1430","article-title":"Clinical, radiographic, and biochemical characterization of multiple myeloma patients with osteonecrosis of the jaw","volume":"14","author":"Raje","year":"2008","journal-title":"Clin. Cancer Res."},{"key":"ref_85","doi-asserted-by":"crossref","first-page":"593","DOI":"10.1200\/JCO.1998.16.2.593","article-title":"Long-term pamidronate treatment of advanced multiple myeloma patients reduces skeletal events. Myeloma Aredia Study Group","volume":"16","author":"Berenson","year":"1998","journal-title":"J. Clin. Oncol."},{"key":"ref_86","doi-asserted-by":"crossref","first-page":"488","DOI":"10.1056\/NEJM199602223340802","article-title":"Efficacy of pamidronate in reducing skeletal events in patients with advanced multiple myeloma","volume":"334","author":"Berenson","year":"1996","journal-title":"N. Eng. J. Med."},{"key":"ref_87","doi-asserted-by":"crossref","first-page":"1735","DOI":"10.1002\/cncr.11701","article-title":"Long-term efficacy and safety of zoledronic acid compared with pamidronate disodium in the treatment of skeletal complications in patients with advanced multiple myeloma or breast carcinoma","volume":"98","author":"Rosen","year":"2003","journal-title":"Cancer"},{"key":"ref_88","doi-asserted-by":"crossref","first-page":"3150","DOI":"10.1200\/JCO.2003.04.105","article-title":"Zoledronic acid versus placebo in the treatment of skeletal metastases in patients with lung cancer and other solid tumors: A phase III, double-blind, randomized trial\u2014The zoledronic acid lung cancer and other solid tumors study group","volume":"21","author":"Rosen","year":"2003","journal-title":"J. Clin. Oncol."},{"key":"ref_89","doi-asserted-by":"crossref","first-page":"1458","DOI":"10.1093\/jnci\/94.19.1458","article-title":"A randomized, placebo-controlled trial of zoledronic acid in patients with hormone-refractory metastatic prostate carcinoma","volume":"94","author":"Saad","year":"2002","journal-title":"J. Natl. Cancer Inst."},{"key":"ref_90","first-page":"377","article-title":"Zoledronic acid versus pamidronate in the treatment of skeletal metastases in patients with breast cancer or osteolytic lesions of multiple myeloma: A phase III, double-blind, comparative trial","volume":"7","author":"Rosen","year":"2001","journal-title":"Cancer J."},{"key":"ref_91","doi-asserted-by":"crossref","first-page":"558","DOI":"10.1200\/JCO.2001.19.2.558","article-title":"Zoledronic acid is superior to pamidronate in the treatment of hypercalcemia of malignancy: A pooled analysis of two randomized, controlled clinical trials","volume":"19","author":"Major","year":"2001","journal-title":"J. Clin. Oncol."},{"key":"ref_92","doi-asserted-by":"crossref","first-page":"1989","DOI":"10.1016\/S0140-6736(10)62051-X","article-title":"First-line treatment with zoledronic acid as compared with clodronic acid in multiple myeloma (MRC Myeloma IX): A randomised controlled trial","volume":"376","author":"Morgan","year":"2010","journal-title":"Lancet"},{"key":"ref_93","doi-asserted-by":"crossref","first-page":"11","DOI":"10.6004\/jnccn.2013.0004","article-title":"Multiple myeloma, version 1.2013","volume":"11","author":"Anderson","year":"2013","journal-title":"J. Natl. Compr. Cancer Netw."},{"key":"ref_94","doi-asserted-by":"crossref","first-page":"2347","DOI":"10.1200\/JCO.2012.47.7901","article-title":"International Myeloma Working Group recommendations for the treatment of multiple myeloma-related bone disease","volume":"31","author":"Terpos","year":"2013","journal-title":"J. Clin. Oncol."},{"key":"ref_95","doi-asserted-by":"crossref","first-page":"1191","DOI":"10.1002\/1097-0142(20010401)91:7<1191::AID-CNCR1119>3.0.CO;2-0","article-title":"Zoledronic acid reduces skeletal-related events in patients with osteolytic metastases","volume":"91","author":"Berenson","year":"2001","journal-title":"Cancer"},{"key":"ref_96","doi-asserted-by":"crossref","first-page":"S31","DOI":"10.1016\/S1040-8428(11)70006-3","article-title":"Anticancer evidence for zoledronic acid across the cancer continuum","volume":"77","author":"Costa","year":"2011","journal-title":"Crit. Rev. Oncol. Hematol."},{"key":"ref_97","doi-asserted-by":"crossref","first-page":"1378","DOI":"10.1158\/1078-0432.CCR-15-1864","article-title":"Bone marker\u2013directed dosing of zoledronic acid for the prevention of skeletal complications in patients with multiple myeloma: Results of the Z-MARK Study","volume":"22","author":"Raje","year":"2016","journal-title":"Clin. Cancer Res."},{"key":"ref_98","doi-asserted-by":"crossref","first-page":"1043","DOI":"10.1038\/leu.2010.62","article-title":"Prognostic variables for survival and skeletal complications in patients with multiple myeloma osteolytic bone disease","volume":"24","author":"Terpos","year":"2010","journal-title":"Leukemia"},{"key":"ref_99","doi-asserted-by":"crossref","first-page":"3955","DOI":"10.1158\/1078-0432.CCR-14-0434","article-title":"Biomarkers of bone remodeling in multiple myeloma patients to tailor bisphosphonate therapy","volume":"20","author":"Patel","year":"2014","journal-title":"Clin. Cancer Res."},{"key":"ref_100","doi-asserted-by":"crossref","first-page":"193","DOI":"10.1002\/cncr.23529","article-title":"Normalization of bone markers is associated with improved survival in patients with bone metastases from solid tumors and elevated bone resorption receiving zoledronic acid","volume":"113","author":"Lipton","year":"2008","journal-title":"Cancer"},{"key":"ref_101","doi-asserted-by":"crossref","first-page":"217","DOI":"10.1016\/j.clon.2012.11.004","article-title":"Skeletal-related events and clinical outcomes in patients with bone metastases and normal levels of osteolysis: Exploratory analyses","volume":"25","author":"Lipton","year":"2013","journal-title":"Clin. Oncol."},{"key":"ref_102","doi-asserted-by":"crossref","first-page":"48","DOI":"10.1001\/jama.2016.19425","article-title":"Effect of longer-interval vs standard dosing of zoledronic acid on skeletal events in patients with bone metastases: A randomized clinical trial","volume":"317","author":"Himelstein","year":"2017","journal-title":"JAMA"},{"key":"ref_103","doi-asserted-by":"crossref","unstructured":"Advisory Task Force on Bisphosphonate-Related Ostenonecrosis of the Jaws, American Association of Oral and Maxillofacial Surgeons (2007). American Association of Oral and Maxillofacial Surgeons position paper on Bisphosphonate-related osteonecrosis of the jaws. J. Oral Maxillofac. Surg., 65, 369\u2013376.","DOI":"10.1016\/j.joms.2006.11.003"},{"key":"ref_104","doi-asserted-by":"crossref","first-page":"5904","DOI":"10.1200\/JCO.2008.16.9300","article-title":"Natural history of osteonecrosis of the jaw in patients with multiple myeloma","volume":"26","author":"Badros","year":"2008","journal-title":"J. Clin. Oncol."},{"key":"ref_105","first-page":"968","article-title":"Osteonecrosis of the jaw in patients with multiple myeloma treated with bisphosphonates: Evidence of increased risk after treatment with zoledronic acid","volume":"91","author":"Dimopoulos","year":"2006","journal-title":"Haematologica"},{"key":"ref_106","doi-asserted-by":"crossref","first-page":"620","DOI":"10.1111\/j.1365-2141.2006.06230.x","article-title":"Incidence, risk factors and management of osteonecrosis of the jaw in patients with multiple myeloma: A single-centre experience in 303 patients","volume":"134","author":"Zervas","year":"2006","journal-title":"Br. J. Haematol."},{"key":"ref_107","doi-asserted-by":"crossref","first-page":"973","DOI":"10.1016\/S1470-2045(10)70198-4","article-title":"Effect of pamidronate 30 mg versus 90 mg on physical function in patients with newly diagnosed multiple myeloma (Nordic Myeloma Study Group): A double-blind, randomised controlled trial","volume":"11","author":"Gimsing","year":"2010","journal-title":"Lancet Oncol."},{"key":"ref_108","first-page":"CD003188","article-title":"Bisphosphonates in multiple myeloma: An updated network meta-analysis","volume":"12","author":"Mhaskar","year":"2017","journal-title":"Cochrane Database Syst. Rev."},{"key":"ref_109","doi-asserted-by":"crossref","first-page":"1385","DOI":"10.1038\/ki.2008.356","article-title":"Bisphosphonate nephrotoxicity","volume":"74","author":"Perazella","year":"2008","journal-title":"Kidney Int."},{"key":"ref_110","doi-asserted-by":"crossref","first-page":"e119","DOI":"10.1016\/S1470-2045(20)30559-3","article-title":"Treatment of multiple myeloma-related bone disease: Recommendations from the Bone Working Group of the International Myeloma Working Group","volume":"22","author":"Terpos","year":"2021","journal-title":"Lancet Oncol."},{"key":"ref_111","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1200\/JOP.2011.000486","article-title":"Acute kidney injury and bisphosphonate use in cancer: A report from the research on adverse drug events and reports (RADAR) project","volume":"9","author":"Edwards","year":"2013","journal-title":"J. Oncol. Pract."},{"key":"ref_112","doi-asserted-by":"crossref","first-page":"2686","DOI":"10.1038\/leu.2017.152","article-title":"Genetic deletion of Sost or pharmacological inhibition of sclerostin prevent multiple myeloma-induced bone disease without affecting tumor growth","volume":"31","author":"Anderson","year":"2017","journal-title":"Leukemia"},{"key":"ref_113","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1016\/j.bone.2016.10.007","article-title":"Role and mechanism of action of sclerostin in bone","volume":"96","author":"Sato","year":"2017","journal-title":"Bone"},{"key":"ref_114","doi-asserted-by":"crossref","unstructured":"Wijenayaka, A.R., Kogawa, M., Lim, H.P., Bonewald, L.F., Findlay, D.M., and Atkins, G.J. (2011). Sclerostin stimulates osteocyte support of osteoclast activity by a RANKL-dependent pathway. PLoS ONE, 6.","DOI":"10.1371\/journal.pone.0025900"},{"key":"ref_115","doi-asserted-by":"crossref","first-page":"4241","DOI":"10.1182\/blood.V126.23.4241.4241","article-title":"Phase 1 dose-escalation study of sotatercept (ACE-011) in combination with lenalidomide and dexamethasone in patients with relapsed and\/or refractory multiple myeloma","volume":"126","author":"Yee","year":"2015","journal-title":"Blood"},{"key":"ref_116","doi-asserted-by":"crossref","first-page":"814","DOI":"10.1111\/bjh.12835","article-title":"Sotatercept in patients with osteolytic lesions of multiple myeloma","volume":"165","author":"Abdulkadyrov","year":"2014","journal-title":"Br. J. Haematol."},{"key":"ref_117","doi-asserted-by":"crossref","first-page":"1139","DOI":"10.1111\/ijcp.12022","article-title":"Denosumab: Mechanism of action and clinical outcomes","volume":"66","author":"Hanley","year":"2012","journal-title":"Int. J. Clin. Pract."},{"key":"ref_118","doi-asserted-by":"crossref","first-page":"756","DOI":"10.1056\/NEJMoa0809493","article-title":"Denosumab for prevention of fractures in postmenopausal women with osteoporosis","volume":"361","author":"Cummings","year":"2009","journal-title":"N. Eng. J. Med."},{"key":"ref_119","doi-asserted-by":"crossref","first-page":"5132","DOI":"10.1200\/JCO.2010.29.7101","article-title":"Denosumab compared with zoledronic acid for the treatment of bone metastases in patients with advanced breast cancer: A randomized, double-blind study","volume":"28","author":"Stopeck","year":"2010","journal-title":"J. Clin. Oncol."},{"key":"ref_120","doi-asserted-by":"crossref","first-page":"813","DOI":"10.1016\/S0140-6736(10)62344-6","article-title":"Denosumab versus zoledronic acid for treatment of bone metastases in men with castration-resistant prostate cancer: A randomised, double-blind study","volume":"377","author":"Fizazi","year":"2011","journal-title":"Lancet"},{"key":"ref_121","doi-asserted-by":"crossref","first-page":"1125","DOI":"10.1200\/JCO.2010.31.3304","article-title":"Randomized, double-blind study of denosumab versus zoledronic acid in the treatment of bone metastases in patients with advanced cancer (excluding breast and prostate cancer) or multiple myeloma","volume":"29","author":"Henry","year":"2011","journal-title":"J. Clin. Oncol."},{"key":"ref_122","doi-asserted-by":"crossref","first-page":"370","DOI":"10.1016\/S1470-2045(18)30072-X","article-title":"Denosumab versus zoledronic acid in bone disease treatment of newly diagnosed multiple myeloma: An international, double-blind, double-dummy, randomised, controlled, phase 3 study","volume":"19","author":"Raje","year":"2018","journal-title":"Lancet Oncol."},{"key":"ref_123","doi-asserted-by":"crossref","first-page":"3082","DOI":"10.1016\/j.ejca.2012.08.002","article-title":"Superiority of denosumab to zoledronic acid for prevention of skeletal-related events: A combined analysis of 3 pivotal, randomised, phase 3 trials","volume":"48","author":"Lipton","year":"2012","journal-title":"Eur. J. Cancer"},{"key":"ref_124","first-page":"340","article-title":"Risk of osteonecrosis of the jaw under denosumab compared to bisphosphonates in patients with osteoporosis","volume":"37","author":"Lehmann","year":"2022","journal-title":"J. Bone Miner. Res."},{"key":"ref_125","doi-asserted-by":"crossref","first-page":"725","DOI":"10.1182\/bloodadvances.2020002378","article-title":"Denosumab compared with zoledronic acid on PFS in multiple myeloma: Exploratory results of an international phase 3 study","volume":"5","author":"Terpos","year":"2021","journal-title":"Blood Adv."},{"key":"ref_126","doi-asserted-by":"crossref","first-page":"233","DOI":"10.1111\/j.1600-0609.2006.00692.x","article-title":"Bortezomib increases osteoblast activity in myeloma patients irrespective of response to treatment","volume":"77","author":"Heider","year":"2006","journal-title":"Eur. J. Haematol."},{"key":"ref_127","doi-asserted-by":"crossref","first-page":"688","DOI":"10.1111\/j.1365-2141.2006.06356.x","article-title":"Bortezomib reduces serum dickkopf-1 and receptor activator of nuclear factor-\u03baB ligand concentrations and normalises indices of bone remodelling in patients with relapsed multiple myeloma","volume":"135","author":"Terpos","year":"2006","journal-title":"Br. J. Haematol."},{"key":"ref_128","first-page":"491","article-title":"Pharmacologic targeting of a stem\/progenitor population in vivo is associated with enhanced bone regeneration in mice","volume":"118","author":"Mukherjee","year":"2008","journal-title":"J. Clin. Investig."},{"key":"ref_129","doi-asserted-by":"crossref","first-page":"2025","DOI":"10.1038\/sj.leu.2404806","article-title":"Bortezomib inhibits human osteoclastogenesis","volume":"21","author":"Krebbel","year":"2007","journal-title":"Leukemia"},{"key":"ref_130","doi-asserted-by":"crossref","first-page":"1771","DOI":"10.1172\/JCI16198","article-title":"Selective inhibitors of the osteoblast proteasome stimulate bone formation in vivo and in vitro","volume":"111","author":"Garrett","year":"2003","journal-title":"J. Clin. Investig."},{"key":"ref_131","doi-asserted-by":"crossref","first-page":"812","DOI":"10.1200\/JCO.2017.76.6402","article-title":"Role of bone-modifying agents in multiple myeloma: American society of clinical oncology clinical practice guideline update","volume":"36","author":"Anderson","year":"2018","journal-title":"J. Clin. Oncol."},{"key":"ref_132","doi-asserted-by":"crossref","first-page":"5374","DOI":"10.1182\/blood-2011-11-392522","article-title":"Effects of induction and maintenance plus long-term bisphosphonates on bone disease in patients with multiple myeloma: The Medical Research Council Myeloma IX Trial","volume":"119","author":"Morgan","year":"2012","journal-title":"Blood"},{"key":"ref_133","doi-asserted-by":"crossref","first-page":"1154","DOI":"10.6004\/jnccn.2019.0049","article-title":"NCCN guidelines insights: Multiple myeloma, version 1.2020: Featured updates to the NCCN guidelines","volume":"17","author":"Kumar","year":"2019","journal-title":"J. Natl. Compr. Cancer Netw."},{"key":"ref_134","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1016\/j.bone.2017.08.003","article-title":"Discontinuation of denosumab therapy for osteoporosis: A systematic review and position statement by ECTS","volume":"105","author":"Tsourdi","year":"2017","journal-title":"Bone"},{"key":"ref_135","doi-asserted-by":"crossref","first-page":"50","DOI":"10.1007\/s00223-018-0394-4","article-title":"Bone mineral density changes after 1 year of denosumab discontinuation in postmenopausal women with long-term denosumab treatment for osteoporosis","volume":"103","author":"Popp","year":"2018","journal-title":"Calcif. Tissue Int."},{"key":"ref_136","doi-asserted-by":"crossref","unstructured":"Anastasilakis, A.D., Makras, P., Yavropoulou, M.P., Tabacco, G., Naciu, A.M., and Palermo, A. (2021). Denosumab discontinuation and the rebound phenomenon: A narrative review. J. Clin. Med., 10.","DOI":"10.3390\/jcm10010152"},{"key":"ref_137","doi-asserted-by":"crossref","first-page":"677","DOI":"10.1530\/EJE-16-1027","article-title":"Increased osteoclastogenesis in patients with vertebral fractures following discontinuation of denosumab treatment","volume":"176","author":"Anastasilakis","year":"2017","journal-title":"Eur. J. Endocrinol."},{"key":"ref_138","doi-asserted-by":"crossref","first-page":"525","DOI":"10.1080\/13696998.2018.1445634","article-title":"A cost-effectiveness analysis of denosumab for the prevention of skeletal-related events in patients with multiple myeloma in the United States of America","volume":"21","author":"Raje","year":"2018","journal-title":"J. Med. Econ."}],"container-title":["Cells"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2073-4409\/11\/15\/2308\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,10]],"date-time":"2025-10-10T23:57:32Z","timestamp":1760140652000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2073-4409\/11\/15\/2308"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,7,27]]},"references-count":138,"journal-issue":{"issue":"15","published-online":{"date-parts":[[2022,8]]}},"alternative-id":["cells11152308"],"URL":"https:\/\/doi.org\/10.3390\/cells11152308","relation":{},"ISSN":["2073-4409"],"issn-type":[{"value":"2073-4409","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,7,27]]}}}